Cargando…

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies. Entrectinib and larotrectinib obtained unprecedented response rates in patients with cancer harboring NTRK rearran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmerini, Emanuela, Frega, Giorgio, Gambarotti, Marco, Frisoni, Tommaso, Cesari, Marilena, Bazzocchi, Alberto, Miceli, Marco, Donati, Davide Maria, Fanti, Stefano, Nanni, Cristina, Benini, Stefania, Longhi, Alessandra, Paioli, Anna, Marrari, Andrea, Hakim, Rossella, Righi, Alberto, Ibrahim, Toni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591071/ https://www.ncbi.nlm.nih.gov/pubmed/37876963 http://dx.doi.org/10.3389/fonc.2023.1252359

Ejemplares similares

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?
por: Righi, Alberto, et al.
Publicado: (2015)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
por: Percy, Catherine, et al.
Publicado: (2021)

High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
por: Palmerini, Emanuela, et al.
Publicado: (2020)

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022)

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
por: Palmerini, Emanuela, et al.
Publicado: (2016)

Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series
por: Ambrosi, Francesca, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
por: Setola, Elisabetta, et al.
Publicado: (2023)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report
por: Pircher, Magdalena, et al.
Publicado: (2021)

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
por: Palmerini, Emanuela, et al.
Publicado: (2022)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
por: Palmerini, Emanuela, et al.
Publicado: (2012)

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
por: Wells, A.E., et al.
Publicado: (2019)

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
por: Zhang, Lei, et al.
Publicado: (2021)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Larotrectinib for solid tumours
Publicado: (2022)

The Efficacy of Molecular Analysis in the Diagnosis of Bone and Soft Tissue Sarcoma: A 15-Year Mono-Institutional Study
por: Benini, Stefania, et al.
Publicado: (2022)

Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?
por: Palmerini, Emanuela, et al.
Publicado: (2015)

Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients
por: Benini, Stefania, et al.
Publicado: (2018)

Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis
por: Righi, A, et al.
Publicado: (2015)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Osteosarcoma follow-up: chest X-ray or computed tomography?
por: Paioli, Anna, et al.
Publicado: (2017)

Erratum to: Osteosarcoma follow-up: chest X-ray or computed tomography?
por: Paioli, Anna, et al.
Publicado: (2017)

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
por: Palmerini, Emanuela, et al.
Publicado: (2021)

Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report
por: Huang, Wen-Kuan, et al.
Publicado: (2023)

Imaging Features of Alveolar Soft Part Sarcoma: Single Institution Experience and Literature Review
por: Spinnato, Paolo, et al.
Publicado: (2023)

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
por: Bielack, S S, et al.
Publicado: (2019)

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
por: DuBois, Steven G., et al.
Publicado: (2018)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s3hvcd3o92grlt3utffra8gdhv